Jack Meehan
Stock Analyst at Barclays
(3.04)
# 1,120
Out of 5,182 analysts
128
Total ratings
69.51%
Success rate
21.33%
Average return
Main Sectors:
Stocks Rated by Jack Meehan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Labcorp Holdings | Maintains: Equal-Weight | $275 → $290 | $263.80 | +9.93% | 17 | Oct 2, 2025 | |
| A Agilent Technologies | Maintains: Underweight | $120 → $125 | $115.55 | +8.18% | 20 | Feb 28, 2024 | |
| WAT Waters | Maintains: Equal-Weight | $275 → $288 | $309.87 | -7.06% | 10 | Aug 3, 2023 | |
| AVTR Avantor | Initiates: Overweight | $33 | $7.90 | +317.72% | 3 | Mar 3, 2021 | |
| ILMN Illumina | Initiates: Underweight | $325 | $127.88 | +154.14% | 8 | Mar 3, 2021 | |
| INMD InMode | Maintains: Overweight | $18 → $19 | $14.40 | +31.94% | 3 | Aug 17, 2020 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $93 → $99 | $196.27 | -49.56% | 7 | Apr 23, 2020 | |
| ICLR ICON Public Limited Company | Maintains: Overweight | $170 → $180 | $102.17 | +76.18% | 2 | Apr 23, 2020 | |
| MYGN Myriad Genetics | Maintains: Underweight | $14 → $10 | $4.78 | +109.21% | 8 | Mar 26, 2020 | |
| IQV IQVIA Holdings | Maintains: Overweight | $192 → $166 | $162.28 | +2.29% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $154 | $169.80 | -9.31% | 7 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $287.84 | +49.39% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $299.45 | +43.60% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $11.59 | - | 10 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $52 → $48 | $36.55 | +31.33% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $720 → $680 | $1,282.45 | -46.98% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $30 | $65.90 | -54.48% | 3 | Oct 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $300 | $469.71 | -36.13% | 5 | Mar 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $40 | $0.91 | +4,306.74% | 1 | Dec 11, 2017 |
Labcorp Holdings
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $275 → $290
Current: $263.80
Upside: +9.93%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120 → $125
Current: $115.55
Upside: +8.18%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275 → $288
Current: $309.87
Upside: -7.06%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $7.90
Upside: +317.72%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $127.88
Upside: +154.14%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18 → $19
Current: $14.40
Upside: +31.94%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93 → $99
Current: $196.27
Upside: -49.56%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170 → $180
Current: $102.17
Upside: +76.18%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14 → $10
Current: $4.78
Upside: +109.21%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192 → $166
Current: $162.28
Upside: +2.29%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $170 → $154
Current: $169.80
Upside: -9.31%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $287.84
Upside: +49.39%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $299.45
Upside: +43.60%
Mar 26, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $11.59
Upside: -
Mar 26, 2020
Upgrades: Overweight
Price Target: $52 → $48
Current: $36.55
Upside: +31.33%
Mar 26, 2020
Upgrades: Equal-Weight
Price Target: $720 → $680
Current: $1,282.45
Upside: -46.98%
Oct 2, 2019
Maintains: Underweight
Price Target: $28 → $30
Current: $65.90
Upside: -54.48%
Mar 18, 2019
Maintains: Overweight
Price Target: $295 → $300
Current: $469.71
Upside: -36.13%
Dec 11, 2017
Initiates: Equal-Weight
Price Target: $40
Current: $0.91
Upside: +4,306.74%